Voyager Therapeutics, Inc. (VYGR)

In May 2025, Voyager Therapeutics reported a Q1 loss and lagged revenue estimates, and published data on ALPL's role in AAV transport across the blood-brain barrier. In June 2025, the stock experienced a significant increase and the company added an APOE program for Alzheimer's disease to its pipeline. In July 2025, Voyager Therapeutics launched a new gene therapy program targeting APOE for Alzheimer's Disease treatment. In August 2025, the company reported its Q2 financial and operating results, including a loss and revenues that lagged estimates, and initiated a single ascending dose trial for its anti-tau antibody (VY7523) for Alzheimer's disease. By September 25, 2025, shares had gained 27% in the preceding thirty days, although they were still down 26% over the last twelve months. In October 2025, the stock soared 11.6% due to investor optimism regarding VY7523, but a sell signal led to a 12.76% fall, and the company's market capitalization fell after a 15% drop in share price.

As a clinical-stage biotechnology company, Voyager Therapeutics, Inc. is primarily focused on research and development of genetic medicines. Its revenue is largely derived from collaborations, milestone payments, and grants, rather than direct product sales to consumers. Therefore, the demand for its products and services in the traditional sense, which would exhibit seasonality, is not applicable at this stage of its business.

Voyager Therapeutics, Inc. is a biotechnology company focused on developing neurogenetic medicines to treat severe neurological diseases, operating within the Health Care sector, specifically in the Biotechnology & Medical Research industry. The company is dedicated to advancing gene therapies for neurological disorders by leveraging its proprietary TRACER AAV capsid discovery platform. Its pipeline includes several preclinical and early clinical programs, including VY7523 for Alzheimer's disease, a SOD1 Silencing Gene Therapy Program for ALS, VY1706 for tauopathies, a GBA1 Gene Therapy Program, an FXN Gene Therapy Program, an Anti-Aβ Antibody Gene Therapy, an APOE Program, and a Huntington's Gene Therapy Program.

Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts, United States, where its primary operations and research and development activities are concentrated.

Voyager Therapeutics' brand reputation is shaped by its scientific progress, pipeline developments, and financial performance. Analyst ratings generally indicate a positive outlook, but the company has faced challenges, including reported quarterly losses and a decline in revenue growth. Positive events, such as the launch of new gene therapy programs and the publication of data on AAV transport across the blood-brain barrier, contribute positively to its scientific and innovative reputation.

Voyager Therapeutics, Inc. has a mixed ownership structure comprising institutional, retail, and individual investors. Institutional investors hold a significant portion of the company's shares, ranging from 44% to 53.47%. Hedge funds own approximately 16% of the shares. Insiders collectively own shares valued at US$3.5 million. Retail investors hold a substantial stake, with some reports indicating around 39% or 75.61% of the company's stock. Major institutional owners include BlackRock, Inc., Armistice Capital, Llc, EcoR1 Capital, LLC, Vanguard Group Inc., Vestal Point Capital, LP, Dimensional Fund Advisors Lp, iShares Russell 2000 ETF, Geode Capital Management, Llc, Erste Asset Management GmbH, Neurocrine Biosciences, Inc., State Street Corp., and Manulife Financial Corp.